期刊文献+

阿德福韦酯致范可尼综合征2例分析 被引量:6

Clinical analysis of Fanconi syndrome induced by adefovir dipivoxil
原文传递
导出
摘要 一、病例资料:病例1:患者男性,42岁。因“发现HBsAg阳性18年,乏力2年余,腰痛2月”于2013年12月就诊。18年前发现HBsAg阳性,HBVDNA〉1×108IU/ml、氨基转移酶异常,服用拉米夫定100mg,1次/d。17年前,患者HBV DNA水平正常,停拉米夫定。5年余前,患者因“乏力不适”入重庆医科大学第二附属医院感染科住院。
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2015年第4期302-303,共2页 Chinese Journal of Hepatology
关键词 肝炎 乙型 慢性 范可尼综合征 阿德福韦酯 临床分析 Hepatitis B, chronic Fanconi syndrome AdefovirDipivoxil Clinicalanalysis
  • 相关文献

参考文献6

  • 1Hadziyannis S J, Tassopoulos NC, Heathcote EJ, et al. Long- term therapy with adefovir dipivoxil for FIBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2005, 352(26): 2673-2681.
  • 2Sam WJ, Akhlaghi F, Rosenbaum SE. Population pharmacokinetics of mycophenoli acid and its 2 glucuronidated metabolites in kidney transplant recipients[J]. J Clin Pharmaol, 2009, 49(2): 185-195.
  • 3Izzedine H, Hulot JS, Launay-Vachcr V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double- blind, randomized, placebo-controlled studies[J]. Kidney Int, 2004, 66(3): 1153-1158.
  • 4Lam YF, Yuen MF, Seto WK, et al. Current antiviral therapy of chronic hepatitis B: efficacy and safety[J]. Curt Hepat Rep, 2011, 10(4): 235-243.
  • 5Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity[J]. Am J Kidney Dis, 2005, 45(5): 804-817.
  • 6曾彩虹,黄倩,范芸,陈浩,杨帆,徐峰,梁少姗,陈惠萍,刘志红.阿德福韦酯相关肾脏损害[J].肾脏病与透析肾移植杂志,2013,22(1):26-31. 被引量:24

二级参考文献19

  • 1Kahn J, Lagakos S, Wulfsohn M, et al dipivoxil with antiretroviral therapy: JAMA, 1999,282(24) :2305-2312.
  • 2Efficacy and safety of adefovir a randomized controlled trial. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS, 1998,12 (14) : 1735-1 744.
  • 3Izzedine H ,Isnard-Bagnis C, Huot IS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS, 2004, 18 (7): 1074-1076.
  • 4KDIGO clinical practice guideline for acute kidney injury. Kidney Int, 2012,2 ( Suppl 1 ) : 1-132.
  • 5Hadziyannis S J, Tassopoulos NC, Heathcote E J, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med,2003,348(9) :800-807.
  • 6Marcellin P, Chang TY, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N EnglJ Ned,2003,348(9) :808716i.
  • 7I-Iadziyannis S J, Tassopoulos NC, Heathcote E J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med,2005,352(26) :2673-2681.
  • 8Benhamou Y, Bochet M, Thibauh V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine- resistant hepatitis B virus: an open-label pilot study. Lancet, 2001, 358(9283) :718-723.
  • 9Harmon H, Bagnis CI, Benhamou Y,et al. The renal tolerance of low- dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant, 2004, 19 ( 2 ) : 386-390.
  • 10Kim Y J, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepato1,2012,27 (2) :306-312.

共引文献23

同被引文献42

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部